Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Peripheral Blood Stem Cells

Effect of peripheral blood progenitor cell dose on hematopoietic recovery: identification of minimal progenitor cell requirements for rapid engraftment

Bone Marrow Transplantation volume 33, pages 589–595 (2004)Cite this article

Summary:

Repeated high-dose chemotherapy (HDC) with stem cell support is advocated for curative treatment of epithelial ovarian cancer patients, requiring large quantities of progenitor cell harvest. Although the switchover to peripheral blood stem cell transplantation has generally made possible the harvest of large quantities of progenitor cells, the minimum threshold is still pertinent for planning the safe conduct of HDC. However, as the minimum threshold for safe peripheral blood stem cell transplantation (PBSCT) is not yet established, this study was designed to clarify the minimum amount of progenitor cells required for prompt recovery of hematopoietic. Retrospective analysis was performed on 52 HDCs administered in 37 ovarian cancer patients. After autologous bone marrow aspiration (10 patients) or peripheral blood stem cell harvest (27 patients), colony-forming unit granulocyte macrophage (CFU-GM) were enumerated prior to cryopreservation. Numbers of CFU-GM were again calculated before reinfusion and the patients were divided into eight groups: 0.13–<0.4, 0.4–<0.7, 0.7–<1.0, 1.0–<3.5, 3.5–<5.0, 5.0–<10.0, 10.0–<20.0 and >20.0 (× 105/kg) . The minimum CFU-GM threshold (× 105/kg) was found to be 1.0–<3.5 for platelets and 3.5–<5.0 for white blood cells. Higher infusion doses did not lead to significant benefits in hematopoietic reconstruction. These results indicate that preservation of a minimum of 7–10 × 105/kg CFU-GM is recommended for the safe conduct of tandem HDCs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Shinozuka T, Murakami M, Miyamoto T et al. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) in ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1991; 10: 193.

    Google Scholar 

  2. Shinozuka T, Miyamoto T, Muramatsu T et al. Long-term follow-up and prognostic analysis in epithelial ovarian cancer treated by high-dose cyclophosphamide, adriamycin and cisplatin (CAP) with autologous bone marrow transplantation (ABMT) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 378a.

    Google Scholar 

  3. Shinozuka T, Hirasawa T, Muramatsu T et al. Long-term results of high dose chemotherapy (HDC) with hematopoietic stem cell support in patients with epithelial ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1998; 17: 375a.

    Google Scholar 

  4. Shinozuka T, Miyamoto T, Muramatsu T et al. High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma. Cancer 1999; 85: 1555–1564.

    CAS  PubMed  Google Scholar 

  5. Shinozuka T, Muramatsu T, Miyamoto T et al. Long-term results and prognostic analysis in advanced and recurrent/refractory epithelial ovarian cancer treated by high-dose cyclophosphamide, adriamycin, and cisplatin with autologous bone marrow transplantation. Int J Clin Oncol 1999; 4: 273–279.

    Google Scholar 

  6. Morgan MA, Stadtmauer EA, Luger SM et al. Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 1997; 67: 272–276.

    CAS  PubMed  Google Scholar 

  7. Fennelly DW, Aghajanian C, Shapiro F et al. Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer. Semin Oncol 1997; 24: S2-26–S2-30.

    Google Scholar 

  8. Wandt H, Birkmann J, Schaefer-Eckart K et al. Sequential cycles of high-dose chemotherapy supported by G-CSF (filgrastim)-mobilized peripheral blood progenitor cells (PBPC) in advanced ovarian cancer: a phase I/II dose escalation study for carboplatin. Proc Am Soc Clin Oncol 1997; 16: 92a.

    Google Scholar 

  9. Schilder RJ, Shea TC . Multiple cycles of high-dose chemotherapy for ovarian cancer. Semin Oncol 1998; 25: 349–355.

    CAS  PubMed  Google Scholar 

  10. Aghajanian C, Fennelly D, Shapiro F et al. Phase II study of ‘dose dense’ high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998; 16: 1852–1860.

    CAS  PubMed  Google Scholar 

  11. Hogge DE, Lambie K, Sutherland HJ et al. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant. Bone Marrow Transplant 2000; 25: 589–598.

    CAS  PubMed  Google Scholar 

  12. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995, 3961–3969.

  13. Scheid C, Draube A, Reiser M et al. Using at least 5 × 106/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transplant 1999; 23: 1177–1181.

    CAS  PubMed  Google Scholar 

  14. Ketterer N, Salles G, Raba M et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148–3155.

    CAS  PubMed  Google Scholar 

  15. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–596.

    CAS  PubMed  Google Scholar 

  16. Pecora AL, Preti RA, Gleim GW et al. CD34+CD33− cells influence days to engraftment and transfusion requirements in autologous blood stem cell recipients. J Clin Oncol 1998; 16: 2093–2104.

    CAS  PubMed  Google Scholar 

  17. Lowenthal RM, Faberes C, Marit G et al. Factors influencing haematopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experience. Bone Marrow Transplant 1998; 22: 763–770.

    CAS  PubMed  Google Scholar 

  18. Gilmore MJML, Prentice HG, Blacklock HA et al. A technique for rapid isolation of bone marrow mononuclear cells using Ficoll–Metrizoate and IBM 2991 blood cell processor. Br J Haematol 1982; 50: 619–626.

    CAS  PubMed  Google Scholar 

  19. Wunder E, Sovalat H, Fritsch G et al. Report on the European workshop on peripheral blood stem cell determination and standardization – Mulhouse, France, February 6–8 and 14–15, 1992. J Hematother 1992; 1: 131–142.

    CAS  PubMed  Google Scholar 

  20. Legros M, Dauplat J, Fleury J et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long term results. J Clin Oncol 1997; 15: 1302–1308.

    CAS  PubMed  Google Scholar 

  21. Bertucci F, Viens P, Gravis G et al. High-dose chemotherapy with hematopoietic stem cell support in patients with advanced epithelial ovarian cancer: analysis of 67 patients treated in a single institution. Anticancer Res 1999; 19: 1455–1462.

    CAS  PubMed  Google Scholar 

  22. Ledermann JA, Herd R, Maraninchi D et al. High dose chemotherapy in ovarian cancer: an analysis of experience of the European Group for blood and marrow transplant (EBMT) over 7 years. Proc Am Soc Clin Oncol 1999; 18: 360a.

    Google Scholar 

  23. Thigpen JT . Dose-intensity in ovarian carcinoma: hold, enough? J Clin Oncol 1997; 15: 1291–1293.

    CAS  PubMed  Google Scholar 

  24. Cure H, Battista C, Guastalla J et al. Phase III randomized trial of high dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (ADC): preliminary results of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 2001; 20: 204a.

    Google Scholar 

  25. Beyer J, Schwella N, Zingsem J et al. Hematopoietic rescue after high dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995; 13: 1328–1335.

    CAS  PubMed  Google Scholar 

  26. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277–284.

    CAS  PubMed  Google Scholar 

  27. Bender JG, To LB, Williams S et al. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329–341.

    CAS  PubMed  Google Scholar 

  28. Shpall EJ, Champlin R, Glaspy JA . Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84–92.

    CAS  PubMed  Google Scholar 

  29. Gandhi MK, Jestice K, Scott MA et al. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999; 23: 9–13.

    CAS  PubMed  Google Scholar 

  30. To LB, Haylock DN, Dyson PG et al. An unusual pattern of hematopoietic reconstitution in patients with acute myeloid leukemia transplanted with autologous recovery phase peripheral blood. Bone Marrow Transplant 1990; 6: 109–114.

    CAS  PubMed  Google Scholar 

  31. Perez-Simon JA, Caballero MD, Corral M et al. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 1998; 38: 385–391.

    CAS  PubMed  Google Scholar 

  32. Perez-Simon JA, Martin D, Caballero D et al. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 1279–1283.

    CAS  PubMed  Google Scholar 

  33. Brandt J, Baird N, Lu L et al. Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro. J Clin Invest 1998; 82: 1017–1027.

    Google Scholar 

  34. Krause DS, Fackler MJ, Civin CI et al. CD34: structure, biology, and clinical utility. Blood 1996; 87: 1–13.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Center for Growth and Reproductive Medicine, Tokai University School of Medicine, Japan

    T Miyamoto, T Shinozuka, H Maeda, T Hirasawa, T Muramatsu, M Murakami & T Makino

  2. Cell Transplantation Unit, Tokai University School of Medicine, Japan

    H Itagaki

  3. Center for Cell and Tissue Regeneration, Tokai University School of Medicine, Japan

    Y Nakamura

Authors
  1. T Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Shinozuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Hirasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Muramatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Makino
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Itagaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Miyamoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miyamoto, T., Shinozuka, T., Maeda, H. et al. Effect of peripheral blood progenitor cell dose on hematopoietic recovery: identification of minimal progenitor cell requirements for rapid engraftment. Bone Marrow Transplant 33, 589–595 (2004). https://doi.org/10.1038/sj.bmt.1704412

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704412

Keywords

Search

Advanced search

Quick links